Highlights include presentations on Xywav, a lower sodium oxybate iindicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Read MoreThe data include a final analysis of the Pitolisant Expanded Access Clinical Evaluation Program, two post-hoc analyses on clinically relevant outcomes from the Phase 3 clinical trials, and analyses that further characterize the cardiac safety profile of WAKIX.
Read MoreHighlights include an oral presentation focusing on the long-term efficacy and safety of DAYVIGO in adults ages 65 and older with insomnia disorder from the Phase 3 clinical study.
Read More
On the intervention night, study participants performed slow breathing while experiencing a relaxing, immersive, virtual reality environment.
Read More
“There were marked shifts in sleep architecture compared to baseline, and some of these evolved over the course of the mission,” says lead author Oliver Piltch.
Read More